Core Viewpoint - Fluor Corporation is facing a class action lawsuit due to alleged violations of the Securities Exchange Act of 1934, with claims that the company and its executives made misleading statements regarding project costs and financial guidance during the class period from February 18, 2025, to July 31, 2025 [1][4]. Company Overview - Fluor Corporation provides engineering, procurement, construction, fabrication, modularization, and project management services, with notable infrastructure projects including the Gordie Howe International Bridge and various highways in Texas [3]. Allegations of the Lawsuit - The lawsuit alleges that Fluor failed to disclose increasing costs related to key infrastructure projects due to subcontractor design errors, price increases, and scheduling delays [4]. - It is claimed that these issues, along with reduced capital spending from customers and economic uncertainty, negatively impacted Fluor's business and financial results [4]. - The lawsuit also states that Fluor's financial guidance for fiscal year 2025 was deemed unreliable and that the effectiveness of its risk mitigation strategies was overstated [4]. Financial Performance - On August 1, 2025, Fluor reported second quarter 2025 non-GAAP earnings per share of $0.43, missing consensus estimates by $0.13, and revenue of $3.98 billion, which represented a 5.9% year-over-year decline and missed estimates by $570 million [5]. - Following the disappointing financial results, Fluor's stock price fell by more than 27% [5]. Lead Plaintiff Process - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Fluor securities during the class period to seek appointment as lead plaintiff in the lawsuit [6]. - The lead plaintiff will represent the interests of all class members and can select a law firm of their choice for litigation [6].

Core Viewpoint - Halper Sadeh LLC is investigating potential breaches of fiduciary duties by certain officers and directors of Live Nation Entertainment, Inc. (NYSE: LYV), urging shareholders to contact the firm to discuss their rights and possible legal actions [1][2]. Group 1: Shareholder Rights and Legal Options - Shareholders who acquired Live Nation stock on or before February 23, 2022, may seek corporate governance reforms, return of funds, court-approved financial incentives, or other benefits [2]. - The firm operates on a contingent fee basis, meaning shareholders would not incur out-of-pocket legal fees or expenses [2]. Group 2: Importance of Shareholder Participation - Shareholder involvement is crucial for improving company policies, practices, and oversight, which can lead to enhanced transparency, accountability, and ultimately, shareholder value [3]. Group 3: Firm's Background and Experience - Halper Sadeh LLC represents global investors affected by securities fraud and corporate misconduct, having successfully implemented corporate reforms and recovered millions for defrauded investors [4].

Core Insights - CarMax, Inc. is currently under investigation for potential violations of federal securities laws following a significant decline in its financial performance [1][2] Financial Performance - For the second quarter of fiscal year 2026, CarMax reported a revenue decline of 6.0% year over year [2] - Total retail used vehicle revenues decreased by 7.2% [2] - Total gross profit fell by 5.6% [2] - Following the financial results announcement, CarMax's stock price dropped by $11.45 per share, approximately 20%, from $57.05 on September 24, 2025, to $45.60 on September 25, 2025 [2]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud and unlawful business practices involving United Homes Group, Inc. (UHG) and its officers or directors [1]. Group 1: Company Developments - On October 20, 2025, six board members of UHG resigned after Executive Chairman Michael Nieri refused to step down or forgo future compensation, despite a special committee's recommendation for strategic changes [2]. - Following the board resignations, UHG's stock price dropped by $2.24 per share, a decline of 52.46%, closing at $2.03 per share on the same day [2]. Group 2: Legal Context - Pomerantz LLP is recognized for its expertise in corporate, securities, and antitrust class litigation, having a long history of advocating for victims of securities fraud and corporate misconduct [3].

Group 1: Jefferies Financial Group Inc. Investigation - Pomerantz LLP is investigating claims on behalf of investors of Jefferies Financial Group Inc. regarding potential securities fraud or unlawful business practices by the company and its officers/directors [1] - Jefferies is facing scrutiny following the bankruptcy of First Brands Group, which has raised questions about financial misrepresentations and its reliance on accounts-receivable-backed financing [2] - Jefferies reported that funds managed by its asset-management unit, Point Bonita Capital, are owed approximately $715 million from companies that purchased parts from First Brands [2] Group 2: Stock Price Impact - Following the news of First Brands' bankruptcy, Jefferies' stock price dropped by $4.66 per share, or 7.88%, closing at $54.44 on October 8, 2025 [2] - The subsequent inquiry by the U.S. Department of Justice into First Brands' dealings with creditors led to an additional decline in Jefferies' stock price by $1.43 per share, or 2.63%, closing at $53.01 on October 9, 2025 [2]

Core Viewpoint - A class action lawsuit has been filed against aTyr Pharma, Inc. and a senior executive for violations of federal securities laws, related to misleading statements about the company's drug trial results [1][5]. Group 1: Lawsuit Details - The lawsuit, titled King v. aTyr Pharma, Inc., is pending in the U.S. District Court for the Southern District of California [1]. - This action follows a previous class action, Munguia v. aTyr Pharma, Inc., which is the first-filed securities class action regarding the same issues [2]. - The King Action claims violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, covering a broader class period from November 7, 2024, to September 12, 2025 [3]. Group 2: Allegations Against aTyr Pharma - The lawsuit alleges that aTyr Pharma and its CEO made false and misleading statements about the Phase 3 EFZO-FIT trial for Efzofitimod, intended for treating pulmonary sarcoidosis [5]. - Throughout the class period, aTyr reportedly issued positive updates about the trial, claiming "remarkable steroid-sparing effects" and confidence in meeting study endpoints [6]. - On September 15, 2025, aTyr disclosed that the trial failed to meet its primary endpoint, revealing no significant change in steroid dosage, which led to a drastic stock price drop of 83.2% [6][7]. Group 3: Investor Information - Investors affected by the alleged misconduct are encouraged to seek appointment as lead plaintiff by December 8, 2025 [8]. - The law firm Shamis & Gentile, P.A. is representing the impacted investors and has a history of recovering over $1 billion for victims of securities fraud [8].

Accessibility StatementSkip Navigation NEW YORK, Oct. 23, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of WPP plc (NYSE: WPP). WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? DEADLINE: December 8, 2025 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/wpp-plc-loss-submission-form/? id=173409&from=4 NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchase ...

Core Points - The Gross Law Firm has issued a notice to shareholders of Cytokinetics, Incorporated regarding potential lead plaintiff appointments in a class action lawsuit related to misleading statements about the New Drug Application (NDA) for aficamten [1][2] - The class period for the lawsuit is from December 27, 2023, to May 6, 2025, during which shareholders are encouraged to register for participation [2] - Allegations include that Cytokinetics misrepresented the timeline for FDA approval and failed to disclose risks associated with not submitting a Risk Evaluation and Mitigation Strategy (REMS), leading to inflated stock prices and subsequent losses for investors when the truth was revealed [1] Company Specifics - Cytokinetics is facing legal scrutiny for allegedly making materially false and misleading statements regarding its NDA submission process for aficamten, which is critical for its market position [1] - The company had multiple pre-NDA meetings with the FDA but chose to submit the NDA without a REMS, which could have significant implications for its regulatory approval process [1] Legal Context - The Gross Law Firm is recognized for its commitment to protecting investor rights and seeks recovery for those who suffered losses due to misleading corporate practices [3] - Shareholders are advised to register by November 17, 2025, to be included in the monitoring of the case's progress [2]

Core Points - The Gross Law Firm has issued a notice to shareholders of Fly-E Group, Inc. regarding a class action lawsuit due to misleading statements about the safety of its lithium batteries, which negatively impacted E-vehicle sales revenue [1] - The class period for the lawsuit is from July 15, 2025, to August 14, 2025, with a significant revenue decline of 32% reported on August 14, 2025, attributed to decreased unit sales and recent lithium-battery accidents [1] - Following the revelation of the financial issues, Fly-E's stock price plummeted approximately 87%, from $7.76 per share to $1.00 per share in one day [1] Company and Industry Summary - Fly-E Group, Inc. faced allegations of providing overly positive statements while concealing material adverse facts about its lithium battery safety, leading to a significant decline in sales and revenue projections [1] - The company reported a substantial decrease in net revenues, primarily driven by a drop in total units sold, which was linked to safety incidents involving its products [1] - The Gross Law Firm is encouraging shareholders to register for the class action lawsuit, with a deadline for lead plaintiff applications set for November 10, 2025 [2]

Core Viewpoint - DJS Law Group is investigating claims against Vera Bradley, Inc. for potential violations of securities laws, particularly focusing on misleading statements and undisclosed information that may have affected investors [1][2]. Investigation Details - The investigation centers on Vera Bradley's Q1 fiscal year 2026 financial results released on June 11, 2025, which disappointed investors. The CEO acknowledged ongoing negative trends in top line and profitability [2]. - Following the release of the disappointing financial results, Vera Bradley's shares experienced a significant decline of 19% on the same day [2]. Legal Representation - DJS Law Group specializes in securities class actions and corporate governance litigation, representing large hedge funds and alternative asset managers [4].